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gust 12, 2013.he study sought to assess the quality of care for heart failure patients who are hospitalized for all causes.Background Performance measures for heart failure target patients with a principal diagnosis of heart failure. However, patients
with heart failure are commonly hospitalized for other causes and may beneﬁt from treatments such as angiotensin-
converting enzyme (ACE) inhibitors for left ventricular (LV) systolic dysfunction.Methods We assessed rates of compliance with care measures for patients hospitalized with acute or chronic heart failure in
the ARIC (Atherosclerosis Risk In Communities) study surveillance catchment area from 2005 to 2009. Rates of
compliance were compared between patients with a principal discharge diagnosis of heart failure and those with
another principal discharge diagnosis.Results Of 4,345 hospitalizations of heart failure patients, 39.6% carried a principal diagnosis of heart failure. Patients with
a principal heart failure diagnosis had higher rates of LV function assessment (89.1% vs. 82.5%; adjusted
prevalence ratio [aPR]: 1.07; 95% conﬁdence interval [CI]: 1.04 to 1.10) and discharge ACE inhibitor/angiotensin
receptor blocker (ARB) in LV dysfunction (64.1% vs. 56.3%; aPR: 1.11; 95% CI: 1.03 to 1.20) as compared to
patients hospitalized for another cause. LV assessment and ACE inhibitor/ARB use were associated with reductions
in 1-year post-discharge mortality (adjusted odds ratio: 0.66, 95% CI: 0.51 to 0.85; adjusted odds ratio: 0.72, 95%
CI: 0.54 to 0.96, respectively) that did not differ for patients with versus without a principal heart failure diagnosis.Conclusions Compared with individuals hospitalized with a principal diagnosis of heart failure, heart failure patients hospitalized
for other causes were less likely to receive guideline recommended care. Quality initiatives may improve care by
targeting hospitalizations with either principal or secondary heart failure diagnoses. (J Am Coll Cardiol 2014;
63:123–30) ª 2014 by the American College of Cardiology FoundationIndividuals with heart failure experience high rates of hos-
pitalization and death (1). Given the signiﬁcant morbidity
and mortality associated with heart failure, a substantialHealth, NYU School of Medicine, New York,
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3; revised manuscript received July 22, 2013,effort has been placed on ensuring that heart failure patients
receive guideline-endorsed care that is associated with im-
proved outcomes. To encourage quality care, the Centers
for Medicare and Medicaid Services (CMS) have developedSee page 131performance measures for hospitalized patients. These
measures currently include evaluation of left ventricular (LV)
systolic function, prescription of an angiotensin-converting
enzyme (ACE) inhibitor or angiotensin receptor blocker
(ARB) for individuals with LV systolic dysfunction at
time of discharge, and discharge instructions (2). The Amer-
ican College of Cardiology Foundation, American Heart
Association, and American Medical Association–Physician
Consortium for Performance Improvement (ACCF/AHA/
AMA-PCPI) have endorsed similar qualitymeasures for adults
with heart failure (3).
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ACE = angiotensin-
converting enzyme
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CI = conﬁdence interval
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pulmonary disease
CMS = Centers for Medicare
and Medicaid Services
eGFR = estimated
glomerular ﬁltration rate
LV = left ventricular
OR = odds ratio
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AHA/AMA-PCPI performance
measures speciﬁcally target patients
whose primary reason for admission
isheart failure,basedon theprincipal
discharge diagnosis code (2,3).
Thus, thesemeasures do not apply
to patients with heart failure with
another principal discharge diag-
nosis. Similarly, current registries
of heart failure hospitalizations,
whichwere created to evaluate and
improve inpatient care, focus on
patients who are hospitalized with
acute heart failure (4–6). None-
theless, the majority of hospitali-
zations of heart failure patients
are for reasons other than heart
failure (7–9).While care measures
for heart failure are reported only
for those patients with a principal
diagnosis of heart failure, some
measures are beneﬁcial to allpatients with heart failure, including LV function assessment
and ACE inhibitor or ARB use in LV systolic dysfunction
(3,10).
The purpose of this study is to determine the quality of
care for individuals hospitalized with a principal diagnosis of
heart failure and individuals with heart failure who are
admitted with a principal diagnosis other than heart failure.
As quality improvement initiatives for heart failure have not
been routinely targeting heart failure patients hospitalized
for other reasons, we hypothesized that patients with heart
failure admitted for other causes would receive less optimal
care for heart failure as compared to individuals who are
speciﬁcally hospitalized for heart failure. We further
hypothesized that quality measures would be associated with
improved outcomes in heart failure, regardless of the reason
for hospitalization.
Methods
The ARIC (Atherosclerosis Risk In Communities) study is
a prospective study of cardiovascular disease among indi-
viduals from 4 U.S. communities (11). To study the preva-
lence of heart failure hospitalizations, the ARIC study began
surveillance of hospital discharge records for all residents of
the 4 communities in 2005. Inclusion criteria for hospitali-
zation review included age >55 years, home address within 1
of the 4 communities, and an International Classiﬁcation of
Diseases-Ninth Revision-Clinical Modiﬁcation (ICD-9-
CM) discharge diagnosis code for heart failure or a related
condition or symptom (398.91, 402.01, 402.11, 402.91,
404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 415.0,
416.9, 425.4, 428.x, 518.4, 786.0x). Discharge diagnosis
codes could be in any position for inclusion (12,13).Eligible hospitalizations were identiﬁed through review of
medical records from hospitals serving the ARIC commu-
nities. Stratiﬁed random sampling was used to identify
hospitalizations for initial abstraction by trained abstractors
(12). Detailed chart abstraction was performed if there was
evidence of symptoms that could be related to heart failure
or physician documentation of heart failure as the reason
for hospitalization. Hospitalizations with detailed chart
abstractions were subsequently adjudicated by a committee
of physicians. The committee classiﬁed hospitalizations into
the following categories: acute decompensated heart failure,
chronic stable heart failure, heart failure unlikely, or un-
classiﬁable (12,13). As previously described (13), classiﬁca-
tion of acute decompensated heart failure was favored if
there was evidence of worsening heart failure symptoms with
augmentation of therapy, while chronic stable heart failure
was selected if there was evidence of heart failure without
change in symptoms.
The population for the present study was selected as
a cohort of individuals with adjudicated heart failure, either
acute decompensated heart failure or chronic stable heart
failure, from 2005 to 2009. We excluded individuals who
were transferred to another hospital or who died during
hospitalization.
We compared the rate of compliance with quality of
care measures for individuals with heart failure who were
hospitalized with a principal diagnosis of heart failure
and those hospitalized for another cause. Principal heart
failure diagnosis was based on ICD-9-CM codes used
by CMS and ACCF/AHA/AMA-PCPI listed in the
primary position (2,3). Additionally, we repeated the
analyses using 3 alternative deﬁnitions of heart failure as
cause of hospitalization. The ﬁrst was determined by the
response to the following question by trained abstrac-
tors: was there evidence from physician notes that heart
failure was the primary reason for hospitalization. This
deﬁnition may best reﬂect the physician perception of
the reason for admission and should not be inﬂuen-
ced by hospital coders. The second alternate deﬁnition
was the ARIC study adjudicated diagnosis of acute
versus chronic heart failure. The third alternate deﬁni-
tion used a combination of the ARIC study deﬁnition
and ICD-9-CM coding. Similar to that used in some
quality initiatives (5), this deﬁnition included hospital-
izations with a principal heart failure diagnosis that was
also adjudicated as acute heart failure.
The primary outcomes were the 2 CMS inpatient heart
failure quality measures available in the ARIC study dataset:
assessment of LV function and discharge prescription of an
ACE inhibitor or ARB for individuals with LV systolic
dysfunction. LV function assessment was determined based
on chart evidence of assessment either prior to or during the
hospitalization.
Rates of compliance for 3 additional discharge measures
were evaluated: prescription of a beta-blocker for individ-
uals with LV systolic dysfunction, prescription of an
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125aldosterone antagonist for individuals with LV systolic
dysfunction and creatinine 2.5 mg/dl in men and
2.0 mg/dl in women, and prescription of anticoagulation
for individuals with atrial ﬁbrillation. These guideline
recommended therapies (10) are not nationally reported
measures but have been considered as emerging measures
of care in heart failure (14). In the ARIC study, informa-
tion regarding anticoagulation at discharge was only
available for a random 20% sample of hospitalizations that
had supplemental data abstracted. For comparison, we also
evaluated the rate of statin use among patients with
a history of coronary heart disease; we were unable to assess
aspirin utilization as information on this medication was
frequently missing.
Demographic characteristics, medical history, and clinical
results were obtained through medical record abstraction.
LV systolic dysfunction was considered present if either the
physician reviewer indicated abnormal systolic function or
the documented ejection fraction was <50%. Edema,
systolic blood pressure, and weight were obtained at time of
admission; we used spline terms for blood pressure up to and
above 140 mm Hg (15). Discharge sodium and estimated
glomerular ﬁltration rate (eGFR) were based on the ﬁnal
sodium and creatinine laboratory values during hospital
admissions, respectively; eGFR was based on the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration)
equation (16) and categorized.
Mortality data were obtained from the National Death
Index and determined for 1 year following discharge.
Mortality data were only available for individuals discharged
during the period of 2005 to 2008.
Statistical analysis. Baseline characteristics were compared
between groups using chi-square and t tests. Poisson
regression (17) was used to estimate the prevalence ratio of
compliance with quality measures for individuals with as
compared to those without a principal heart failure diag-
nosis, after adjustment for a priori selected covariates of age,
sex, race, insurance, systolic blood pressure, eGFR, and
history of coronary heart disease, diabetes, asthma, chronic
obstructive pulmonary disease (COPD), dialysis, stroke, and
atrial ﬁbrillation.
Logistic regression was used to determine the associations
of a primary discharge diagnosis of heart failure and
adherence to quality measures with mortality following
discharge. Covariates in the models were those available in
the ARIC study dataset that were similar to predictors of
mortality in a prior study of hospitalized patients with heart
failure and included age, systolic blood pressure, eGFR,
sodium, presence of edema, statin at discharge, and history
of coronary heart disease, diabetes, asthma, COPD, stroke,
and depression (15) plus the additional demographic
covariates of race, sex, and insurance. We developed a
primary model and then a second model with an interaction
term of the quality measure and an index of whether heart
failure was the principal discharge diagnosis. Logistic
regression models were also developed for both individualswith a principal diagnosis of heart failure and those with
another principal diagnosis.
Several sensitivity analyses were performed. First, we
determined the association between each of the 3 alternative
deﬁnitions of heart failure. Second, we repeated our primary
analysis with limiting inclusion to CMS heart failure diag-
nosis in the primary or secondary position. This analysis was
done as hospitalizations screened and potentially adjudicated
in the ARIC study as heart failure included codes outside of
the CMS coding deﬁnition of heart failure, including such
diagnoses as rheumatic heart failure, cor pulmonale, and
shortness of breath. Third, we estimated the adjusted
prevalence ratio of the measures for individuals with as
compared to those without a principal heart failure diagnosis
by eGFR categories and COPD status.
All statistical analyses accounted for the sampling design
of the ARIC surveillance study. Statistical signiﬁcance was
pre-speciﬁed at an alpha level of 0.05 (2-tailed). Analyses
were performed using Stata version 12 (StataCorp, College
Station, Texas).
Results
There were 4,345 hospitalizations that were sampled and
adjudicated as acute decompensated or chronic heart failure
and included in the study. Of these, 1,723 (39.7%) hospi-
talizations carried a principal diagnosis of heart failure.
Hospitalizations with a principal diagnosis of heart failure
were more likely to have been adjudicated as acute decom-
pensated heart failure as compared with those with another
principal diagnosis (97.4% vs. 70.9%, p < 0.001). Black race
was more commonly observed among heart failure patients
hospitalized with a principal diagnosis of heart failure
(Table 1). Individuals with a principal diagnosis other than
heart failure had a higher prevalence of a number of non-
cardiovascular comorbid conditions, including COPD and
depression (Table 1).
Of all acute or chronic heart failure hospitalizations,
85.1% had a record of LV function assessment. Individuals
with a principal diagnosis of heart failure were more likely to
have received assessment of LV function as compared to
individuals with another principal diagnosis (Table 2).
Among individuals with LV systolic dysfunction, 59.7%
were prescribed an ACE inhibitor or ARB at discharge;
individuals with a principal diagnosis of heart failure had
a 14% higher rate of prescription for an ACE inhibitor or
ARB at discharge, with similar results after adjustment for
important covariates (Table 2). As compared with individual
with another principal diagnosis, individuals with a principal
diagnosis of heart failure had a similar rate of prescription
for b-blockers and anticoagulants at time of discharge, when
appropriate. Both groups had low rates of aldosterone an-
tagonist utilization for individuals with LV systolic dys-
function and creatinine levels below the recommended
threshold, with 17.1% overall compliance with this measure.
Nonetheless, individuals admitted with a principal diagnosis
Table 1
Baseline Characteristics of Hospitalized Heart Failure
Patients With a Principal Diagnosis of Heart Failure
and Those With Another Principal Diagnosis
Principal Heart
Failure Diagnosis
(n ¼ 1,723)
Other Principal
Diagnosis
(n ¼ 2,622) p Value
Age, yrs 75.1  0.3 75.2  0.2 0.91
Age category, yrs 0.29
55–64 19.5 19.8
65–74 26.1 23.9
75–84 33.8 36.6
>85 20.7 19.6
Female 53.0 52.6 0.85
Race <0.001
White 63.0 72.0
Black 33.9 23.5
other 3.1 4.6
Insurance 0.03
None 5.0 3.1
Medicaid 4.0 4.7
Medicare 16.3 15.1
Other insurance 18.4 20.0
Medicare/Medicaid 15.6 14.1
Medicare/other 40.8 42.7
ARIC classiﬁcation <0.001
Acute decompensated 97.4 70.9
Chronic 2.6 29.1
Systolic HF 54.1 48.1 <0.001
Increased edema 67.7 47.6 <0.001
Admission SBP, mm Hg 146.0  0.9 137.8  0.7 <0.001
Discharge sodium, mmol/l 138.6  0.1 138.7  0.1 0.51
Discharge eGFR,
ml/min/1.73 m2
46.6  0.6 51.8  0.6 <0.001
Medical history
Anemia 29.0 29.9 0.61
Current smoker 13.4 15.8 0.06
COPD 30.6 39.1 <0.001
Asthma 6.6 9.9 0.001
Coronary heart
disease
46.9 43.4 0.05
Deﬁbrillator 9.9 7.8 0.04
Hypertension 85.3 82.1 0.03
Diabetes 48.9 45.2 0.04
Dialysis 7.1 7.4 0.71
Stroke/TIA 17.7 20.9 0.02
Depression 14.4 18.0 0.008
Atrial ﬁbrillation 36.8 35.5 0.43
Statin at discharge 47.2 45.9 0.44
Length of stay 5.7  0.3 8.7  0.4 <0.001
Values are mean  SE or %.
ARIC ¼ Atherosclerosis Risk In Communities; COPD ¼ chronic obstructive pulmonary disease;
eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; TIA ¼ transient ischemic attack;
SBP ¼ systolic blood pressure.
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126of heart failure were more likely to have received aldosterone
antagonists at discharge (Table 2). Among patients with
coronary heart disease, 46% were prescribed a statin at time
of discharge.
Mortality follow-up was available for the 3,201 individ-
uals discharged between 2005 and 2008. Among these
individuals, the 1-year mortality rate was 26.0% and wassimilar for individuals with and without a principal diagnosis
of heart failure (25.6 vs. 26.2; p ¼ 0.76). After adjusting for
covariates, the presence of a principal diagnosis of heart
failure was associated with an odds ratio for mortality of 0.92
(95% conﬁdence interval [CI]: 0.76 to 1.13) as compared
with a principal diagnosis other than heart failure.
Individuals hospitalized with heart failure with assessment
of LV systolic function had an adjusted odds ratio (OR) for
mortality following discharge of 0.66 (95% CI: 0.51 to 0.85)
as compared with individuals who did not have LV assess-
ment. There was no difference in the relationship of LV
assessment and mortality for individuals with versus without
a principal diagnosis of heart failure (p interaction ¼ 0.79)
(Table 3). Prescription of an ACE inhibitor or ARB at
discharge was associated with improved survival for indi-
viduals with LV systolic dysfunction (adjusted OR for
mortality: 0.72; 95% CI: 0.54 to 0.96). The association
between ACE inhibitor/ARB use at discharge and subse-
quent mortality was similar for individuals with and without
a principal diagnosis of heart failure (p interaction ¼ 0.66)
(Table 3).
There was no difference between the 2 groups in the
association between 2 of the emerging process measures and
mortality. Beta-blocker use was associated with improved
post-discharge mortality for individuals with LV systolic
dysfunction who were hospitalized both with and without
a principal diagnosis of heart failure (p interaction ¼ 0.83).
Use of aldosterone antagonist for individuals with LV
dysfunction was associated with a reduction in post-
discharge mortality that did not reach statistical signiﬁ-
cance (adjusted OR: 0.69; 95% CI: 0.47 to 1.01) and was
similar between groups (p interaction ¼ 0.41). Conversely,
the associated beneﬁt of anticoagulation for atrial ﬁbrillation
differed between groups (p interaction ¼ 0.04). Anti-
coagulation for atrial ﬁbrillation was associated with
improved mortality among individuals hospitalized with
a principal diagnosis other than heart failure; this association
was not observed among individuals hospitalized with
a principal heart failure diagnosis (Table 3).
Sensitivity analyses. Results of the primary analyses were
similar when using the 3 alternative deﬁnitions of heart
failure as the responsible diagnosis for admission. Individ-
uals for whom the physician documented heart failure as the
reason for hospitalization had higher rates of LV assessment
(87.7% vs. 79.2%; p < 0.0001) and ACE inhibitor or ARB
at discharge for LV systolic dysfunction (62.3% vs. 52.9%;
p < 0.001) as compared with individuals with heart failure
for whom the physician did not document heart failure as
the reason for hospitalization. The differences between these
2 groups persisted after multivariate adjustment (Table 4).
As compared with individuals hospitalized with ARIC study
adjudicated chronic heart failure, individuals hospitalized
with adjudicated acute heart failure had a higher rate of LV
assessment (87.4% vs. 75.0%; p < 0.0001) and a nonsignif-
icant increase in ACE inhibitor or ARB utilization (60.5%
vs. 55.7%; p ¼ 0.13) (Table 4). Individuals hospitalized with
Table 2 Quality and Process Care Measures for Hospitalized Heart Failure Patients, by Principal Diagnosis
Care Measure
Patients Assessed
for Measure
% Meeting Measure
p Value
Adjusted* Prevalence Ratio,
Principal HF Versus OtherPrincipal HF Diagnosis Other Principal Diagnosis
LV assessment 4,345 89.1 82.5 <0.0001 1.07 (1.04–1.10)
ACE inhibitor/ARB for LV dysfunction 2,275 64.1 56.3 0.002 1.11 (1.03–1.20)
b-blocker for LV dysfunction 2,275 81.4 77.9 0.08 1.03 (0.98–1.08)
Anticoagulation for atrial ﬁbrillation 350 50.6 44.8 0.35 1.16 (0.89–1.52)
Aldosterone antagonist for LV
dysfunction
1,919 19.8 15.0 0.02 1.35 (1.06–1.72)
Values are n, %, or prevalence ratio (95% conﬁdence interval). *Adjusted for age, sex, race, insurance, systolic blood pressure, estimated glomerular ﬁltration rate, and history of coronary heart disease,
diabetes, asthma, chronic obstructive pulmonary disease, dialysis, stroke, and atrial ﬁbrillation.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; HF ¼ heart failure; LV ¼ left ventricular.
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127adjudicated acute heart failure and a principal discharge
diagnosis of heart failure also had higher rates of LV
assessment (89.2% vs. 82.5%; p < 0.0001) and ACE
inhibitor or ARB at discharge for LV systolic dysfunction
(64.2% vs. 56.3%; p < 0.01) as compared with individuals
with adjudicated chronic heart failure or a principal diag-
nosis other than heart failure. When we considered only
hospitalizations with a heart failure diagnosis deﬁned by the
CMS deﬁnition, a total of 3,810 individuals were included
in the analyses. The results for these individuals were nearly
identical to the primary analysis (data not shown). Among
subgroups of eGFR categories and individuals with COPD,
the adjusted prevalence ratios of the measures of LV
assessment, prescription of an ACE inhibitor or ARB, and
prescription of a b-blocker for individuals with versus
without a principal diagnosis of heart failure were similar to
the results of the overall cohort (Online Table).
Discussion
Substantial efforts have been made to measure and improve
the quality of care delivered to heart failure patients in both
the inpatient and outpatient setting (2–6,18). Inpatient
quality of care has focused primarily on patients with
a diagnosis of acute heart failure, commonly identiﬁed by
principal discharge diagnosis code (2–6). Our results suggest
that quality improvement initiatives have had an effect on
care delivery in a representative sample of 4 communities: we
found that 2 commonly used measures of heart failure care,
assessment of LV systolic function and prescription of anTable 3 Relationship of Quality and Process Care Measures With 1-Y
Care Measure
Principal HF Diagn
Unadjusted
LV assessment 0.55 (0.36–0.83)
ACE inhibitor/ARB for LV dysfunction 0.51 (0.35–0.75)
b-blocker for LV dysfunction 0.52 (0.33–0.80)
Anticoagulation for atrial ﬁbrillation 0.77 (0.33–1.81)
Aldosterone antagonist for LV dysfunction 0.83 (0.50–1.34)
Values are odds ratio (95% conﬁdence interval). *Adjusted for age, sex, race, insurance, systolic blood
and history of coronary heart disease, diabetes, asthma, chronic obstructive pulmonary disease, stroke,
Abbreviations as in Table 2.ACE inhibitor or ARB at time of discharge for patients with
LV systolic dysfunction, were more likely to be achieved in
patients with a principal diagnosis of heart failure as
compared to those with another principal diagnosis.
Conversely, b-blocker therapy for LV systolic dysfunction
did not differ between groups. Of note, b-blocker therapy is
not a CMS quality measure and became an ACCF/AHA/
AMA-PCPI performance measure for patients with a prin-
cipal diagnosis of heart failure only as of 2012 (2,3), so there
might not have been incentives to target this therapy
speciﬁcally to patients with a principal diagnosis of heart
failure during the study period.
We found that the majority of hospitalizations for indi-
viduals with heart failure had a principal diagnosis that was
not heart failure, a ﬁnding consistent with previous studies
(7–9). Although hospitalizations with a principal diagnosis
other than heart failure generally are not subject to heart
failure quality improvement measures, the metrics we eval-
uated are consistent with guideline-recommended care for
all heart failure patients (10). Thus, these measures should
have clinical value for heart failure patients hospitalized for
other causes. We found that, as compared with individuals
with a principal diagnosis of heart failure, heart failure
patients hospitalized with a nonheart failure diagnosis had
a 7% lower rates of LV functional assessment, a 10% lower
rate of prescription for an ACE inhibitor or ARB at time of
discharge, and lower rates of prescription for an aldosterone
antagonist. These data suggest that heart failure patients
admitted for other diagnoses may be receiving lower rates of
guideline-concordant care as compared to patients whoseear Mortality Following HF Hospitalization, by Principal Diagnosis
osis Other Principal Diagnosis
Adjusted* Unadjusted Adjusted*
0.63 (0.41–0.98) 0.64 (0.47–0.86) 0.68 (0.49–0.94)
0.67 (0.43–1.03) 0.67 (0.48–0.95) 0.76 (0.52–1.10)
0.51 (0.32–0.84) 0.49 (0.33–0.73) 0.48 (0.31–0.75)
1.61 (0.60–4.34) 0.41 (0.17–0.99) 0.36 (0.13–0.95)
0.79 (0.46–1.36) 0.65 (0.38–1.12) 0.57 (0.32–0.99)
pressure, estimated glomerular ﬁltration rate, sodium, presence of edema, statin at discharge,
and depression.
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128primary reason for hospitalization is acute heart failure.
These ﬁndings are notable as we found selected measures to
have associations with mortality that provided comparable
beneﬁt for individuals both with and without a principal
heart failure diagnosis in a real-world setting. These results
suggest that improving compliance with processes of care
such as LV assessment and, as appropriate, discharge pre-
scriptions for ACE inhibitors/ARBs, beta-blockers, aldo-
sterone antagonists, and anticoagulants, may result in
improved survival among both individuals with a primary
diagnosis of heart failure as well as those with a secondary
diagnosis of heart failure. The potential for improved
outcomes with quality care for individuals with a secondary
heart failure diagnosis is particularly important, as these
individuals are more commonly seen in the hospital and are
less likely to receive heart failure-related therapies than
individuals with a principal heart failure diagnosis.
The ACCF/AHA/AMA-PCPI recently updated their
recommendations for performance measures for heart failure
(3) A number of the measures, including LV systolic
assessment and ACE inhibitors or ARBs and b-blockers for
LV systolic dysfunction, applied to both the inpatient and
outpatient clinical encounters. In these recommendations,
while outpatient measures are applicable to all patients with
a diagnosis of heart failure, inpatient measures are speciﬁc
to those patients for whom heart failure is the primary cause
for hospitalization. In this paradigm, a hospitalization in
which heart failure is either a secondary reason for hospital-
ization or a stable, chronic condition may be similarly subject
to heart failure quality measures as an outpatient encounter.
Our data suggest that there may be a missed opportunity to
deliver these quality metrics to heart failure patients whose
primary reason for hospitalization is a different cause.
Our study included only individuals with adjudicated
acute or chronic heart failure, both of whom are appropriate
for guideline concordant care such as ACE inhibitors for
LV systolic dysfunction. One potential limitation of ex-
panding performance measurement to heart failure patients
who are hospitalized for any cause is a loss of speciﬁcity for
heart failure. Indeed, a prior study from the ARIC study
demonstrated that the ICD-9 code of 428 in any position
carried a 23% false positive rate for acute or chronic heart
failure as compared with only 3% for this code as the
principal diagnosis (13). However, the imperfect speciﬁcity
may represent an opportunity for coding improvement,
particularly as increased coding for heart failure may be
inappropriately driven by reimbursement incentives (19).
More so, expanding quality measures to individuals with
a heart failure diagnosis in any position will signiﬁcantly
increase the sensitivity for detection of heart failure; in the
ARIC study, the sensitivity was 0.95 for ICD-9 code 428
in any position versus 0.36 in the primary position (13).
We observed that adherence to care measures such as LV
evaluation and ACE inhibitors or ARBs for LV dysfunction
was associated with reduced mortality among patients with
heart failure. Prior studies have questioned whether inpatient
JACC Vol. 63, No. 2, 2014 Blecker et al.
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129care measures have direct clinical beneﬁts. For instance, in
a large registry of heart failure hospitalizations, performance
measures were generally found to have no association with
outcomes (20) and other studies have been inconclusive
(21,22). Nonetheless, care measures have been associated
with improved outcomes in the outpatient setting (23).
Further evaluation of the effect of current heart failure care
measures on mortality and rehospitalization is needed.
Study limitations. Our ﬁndings must be interpreted with
several caveats. First, the analysis was limited by the inability
to assess physician exceptions for not adhering with mea-
sures. For instance, we were unable to determine if echo-
cardiography was previously performed but not recorded in
the chart or was planned for post-discharge and we could
not detect if an ACE inhibitor was not prescribed because
an individual had an allergy to this medication or had acute
kidney injury. We partly addressed this issue through our
sensitivity analyses and found that adherence to performance
measures was similar for individuals with different levels
of kidney disease and those with COPD. Second, residual
measured and unmeasured confounding may account for
some of the ﬁndings in this observational study. Third, due
to limitations in the data, we were unable to assess the
relationship of the selected performance measures with
clinically important outcomes such as rehospitalizations,
quality of life, and costs. Fourth, due to the design of the
ARIC study, hospitalizations were fully abstracted only if
there was evidence of worsening symptoms of heart failure.
Therefore, hospitalizations adjudicated as chronic stable
heart failure represented only a subsample of chronic stable
heart failure hospitalizations in the ARIC study communi-
ties. The reduced number of chronic heart failure hospital-
izations included in the study partly accounts for the ﬁnding
of a high rate (70.9%) of acute decompensated heart failure
among hospitalizations with a principal diagnosis other than
heart failure. Nonetheless, this ﬁnding can be explained by
the fact that heart failure decompensation is commonly
precipitated by another condition that may result in hospi-
talization (10); in this context, a patient who is principally
hospitalized for pneumonia or renal failure will also have
concurrent acute heart failure. Fifth, we deﬁned LV systolic
dysfunction as an ejection fraction of <50%, based on the
ARIC study abstraction deﬁnition. While this cutoff is
commonly used in research (8,24), performance measures
typically deﬁne LV systolic dysfunction as an ejection frac-
tion of <40% (2,3). Sixth, the study was limited to patients
with heart failure, so patient characteristics and outcomes
may be different from other individuals in the ARIC study
communities. Finally, while this study included a sample of
hospitalizations from 4 U.S. communities, the results may
not reﬂect practice patterns nationally.
Conclusions
Among a community sample of 4,345 heart failure–related
hospitalizations, 85.1% of patients had LV functionassessment and 59.7% of patients with LV systolic
dysfunction were prescribed an ACE inhibitor or ARB at
discharge, suggesting there is substantial opportunity for
improvement in care delivered to patients hospitalized with
heart failure. In particular, patients hospitalized with
a principal diagnosis other than heart failure were less likely
to receive care measures as compared to those with a prin-
cipal diagnosis of heart failure, although compliance with
performance measures showed a similar survival beneﬁt in
both groups. Because heart failure patients are commonly
admitted for a variety of conditions, quality performance
initiatives may have an opportunity to improve the care for
many heart failure patients by targeting hospitalizations with
both a principal and secondary heart failure diagnosis. Given
the potential for reduced mortality with improved quality of
care for the 3 million annual hospitalizations of heart failure
patients for causes other than heart failure (9), the potential
public health impact of such initiatives is great.Acknowledgements
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